The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer.

IF 4 2区生物学 Q2 MICROBIOLOGY

Frontiers in Microbiology Pub Date : 2025-05-27 eCollection Date: 2025-01-01 DOI:10.3389/fmicb.2025.1591745

Xiaoying Ren, Lixiang Zheng, Ling Huang, Jiangbo Zhao

{"title":"The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer.","authors":"Xiaoying Ren, Lixiang Zheng, Ling Huang, Jiangbo Zhao","doi":"10.3389/fmicb.2025.1591745","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is the most prevalent malignancy among women worldwide and is a major contributor to cancer-related mortality. The tumor microenvironment (TME), composed of tumor cells, immune infiltrates, fibroblasts, and vascular components, is critically involved in tumor initiation, metastatic progression, and therapeutic response. In recent years, therapies targeting the TME have undergone rapid advancements, with the objective of enhancing antitumor immunity. Concurrently, mounting evidence underscores the pivotal role of the gut microbiota and its metabolites in modulating host immunity, influencing metabolic homeostasis, inflammation, and immune equilibrium. The composition and diversity of the gut microbiome influence breast cancer progression and patients' responses to immunotherapy. Therefore, modulating the gut microbiota is a promising strategy to enhance the clinical outcomes of TME-targeted immunotherapies. In this review, we discuss the influence of gut microbiota and its derived metabolites on breast cancer progression and immunotherapy prognosis and explore potential strategies to optimize immunotherapy through gut microbiota modulation.</p>","PeriodicalId":12466,"journal":{"name":"Frontiers in Microbiology","volume":"16 ","pages":"1591745"},"PeriodicalIF":4.0000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149186/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fmicb.2025.1591745","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer is the most prevalent malignancy among women worldwide and is a major contributor to cancer-related mortality. The tumor microenvironment (TME), composed of tumor cells, immune infiltrates, fibroblasts, and vascular components, is critically involved in tumor initiation, metastatic progression, and therapeutic response. In recent years, therapies targeting the TME have undergone rapid advancements, with the objective of enhancing antitumor immunity. Concurrently, mounting evidence underscores the pivotal role of the gut microbiota and its metabolites in modulating host immunity, influencing metabolic homeostasis, inflammation, and immune equilibrium. The composition and diversity of the gut microbiome influence breast cancer progression and patients' responses to immunotherapy. Therefore, modulating the gut microbiota is a promising strategy to enhance the clinical outcomes of TME-targeted immunotherapies. In this review, we discuss the influence of gut microbiota and its derived metabolites on breast cancer progression and immunotherapy prognosis and explore potential strategies to optimize immunotherapy through gut microbiota modulation.

查看原文本刊更多论文

肠道微生物群在形成肿瘤微环境和乳腺癌免疫治疗中的作用。

乳腺癌是全世界妇女中最常见的恶性肿瘤，也是癌症相关死亡率的主要原因。肿瘤微环境（TME）由肿瘤细胞、免疫浸润、成纤维细胞和血管成分组成，在肿瘤的发生、转移进展和治疗反应中起着关键作用。近年来，以TME为靶点的治疗方法取得了快速进展，目的是增强抗肿瘤免疫。同时，越来越多的证据强调了肠道微生物群及其代谢物在调节宿主免疫、影响代谢稳态、炎症和免疫平衡中的关键作用。肠道微生物组的组成和多样性影响乳腺癌的进展和患者对免疫治疗的反应。因此，调节肠道微生物群是提高tme靶向免疫治疗临床效果的一种有希望的策略。在这篇综述中，我们讨论了肠道菌群及其衍生代谢物对乳腺癌进展和免疫治疗预后的影响，并探讨了通过肠道菌群调节优化免疫治疗的潜在策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Microbiology MICROBIOLOGY-

CiteScore

7.70

自引率

9.60%

发文量

4837

审稿时长

14 weeks

期刊介绍： Frontiers in Microbiology is a leading journal in its field, publishing rigorously peer-reviewed research across the entire spectrum of microbiology. Field Chief Editor Martin G. Klotz at Washington State University is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.